What You Need to Know About Bio-Rad Laboratories, Inc.'s Q4 Earnings
Bio-Rad Laboratories, Inc.'s fiscal Q4 earnings report was released on Wednesday, November 04. Let's dive in to see if (BIO) missed or beat analyst's expectations.Tudor Pop
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Jenna Brashear
Jenna Brashear
Michael Rose
Tudor Pop
| Share Statistics | BIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9,809.2 | $3,333.2 | 79% |
|
| Shares Out (Mil) | 26.9 | 107.2 | 35% |
|
| Institutional Ownership | 46.9% | 88.4% | 20% |
|
| Float (Mil) | 21.5 | 79.2 | 30% |
|
| Beta | 1.06 | 1.15 | 63% |
|
| Avg Daily Volume (000s) | 285 | 958 | 49% |
|
| Price Change (52-week) |
17.8% | 81.2% | 71% |
|
| Growth | BIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 0.3% | 7.5% | 19% |
|
| Net Income (5yr) | (27.6%) | (12.9%) | 15% |
|
| EPS (5yr) | (26.1%) | 1.4% | 10 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 59.5% | (15.0%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 3 | 3 | |
| Current EPS | $2.830 | $9.607 | $9.907 | |
| Month Ago EPS | $3.020 | $9.450 | $9.747 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | $2.907 | $9.483 | $10.028 | |
| Year/Year Chg | (83.4%) | (65.5%) | (63.3%) | |
| Financials | BIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2,593 | $816 | 63% |
|
| Net Income (TTM) (Mil) | $1,023 | ($24) | 86% |
|
| EPS (TTM) | $38.051 | ($0.300) | 99% |
|
| Operating Cash Flow (TTM) (Mil) | $468 | $79 | 70% |
|
| Net Cash Flow (TTM) (Mil) | $69 | $4 | 73% |
|
| Long-Term Debt (Q1) (Mil) | $931 | $263 | 65% |
|
| Enterprise Value (Q1) (Mil) | $9,671 | $3,667 | 73% |
|
| Valuation | BIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.27 | 2.97 | 39% |
|
| P/E | 9.5 | 33.8 | 19% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.4 | na |
|
| Ratios | BIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 52.2% | 47.5% | 64% |
|
| Net Margin | 39.5% | (3.5%) | 94% |
|
| ROA | 10.0% | (4.5%) | 86% |
|
| ROE | 14.3% | (3.6%) | 69% |
|
| Liabilities to Assets | 29.5% | 40.9% | 21% |
|
| F-Score | 6 | 5 | 67% |
|
Bio-Rad Laboratories, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors